Abstract

Inspire Medical Systems will release first-quarter 2026 results on May 4, 2026 Post Market, and this preview outlines consensus revenue, profit metrics, EPS expectations, and the main drivers that investors are watching into the print.

Market Forecast

For the first quarter of 2026, market forecasts indicate revenue of 202.45 million US dollars, up 3.73% year over year; adjusted EPS is projected at -0.28, implying a 14.52% year-over-year decline, and EBIT is modeled at -13.87 million US dollars, implying a 12.59% year-over-year decline. Forecasts for quarterly gross margin and net margin are not disclosed in the available estimates. The company’s core business is expected to remain driven by system implants and generator sales with steady demand, while execution should hinge on procedure throughput and scheduling; adopters will be looking for commentary on utilization and center productivity. The most promising growth vector in focus is the ongoing adoption of the Inspire V platform and international expansion, though quantitative segment revenue and year-over-year growth details for the quarter are not disclosed.

Last Quarter Review

In the prior quarter, Inspire Medical Systems reported revenue of 269.08 million US dollars (up 12.25% year over year), a gross profit margin of 86.59%, GAAP net profit attributable to the parent company of 136.00 million US dollars, a net profit margin of 50.58%, and adjusted EPS of 1.62 (up 40.87% year over year). A notable operational highlight was outperformance versus expectations: revenue surpassed the quarter’s consensus by 3.41 million US dollars and adjusted EPS exceeded expectations by 0.74, while EBIT of 46.11 million US dollars rose 44.62% year over year, reflecting strong operating leverage in the seasonally strongest quarter. While a detailed revenue breakdown by product or geography is not disclosed in the dataset, the quarter’s strength was underpinned by higher procedure volumes and continued center productivity, with upgrades and system placements sustaining momentum into year-end.

Current Quarter Outlook

Core revenue engine this quarter

Management commentary in recent months and the cadence of prior-year results suggest first-quarter revenue typically reflects seasonality after a strong fourth quarter, and the forecasts of 202.45 million US dollars (up 3.73% year over year) are consistent with that pattern. The key variable for revenue execution in the current quarter is the throughput of scheduled procedures at existing centers, which governs both system revenue and generator-related pull-through. Investors will be looking closely at scheduling backlogs, cancellation rates, and the pace of new-patient onboarding, as these operational details flow directly into realized revenue for the period. Another point of emphasis is pricing and mix. Average revenue per procedure can move with product mix, including the share of Inspire V generators, replacement activity, and any shifts between domestic and international sales. While the aggregate estimate calls for year-over-year revenue growth, the projected decline in EBIT and EPS highlights that first-quarter operating expense growth and mix may offset gross profit expansion. In other words, the revenue base appears durable, but profitability in the quarter will depend on how cost growth and product mix interact with realized volumes. Reimbursement continuity remains a critical backdrop for the quarter’s revenue conversion, with prior coding clarifications introducing some operational complexity for hospitals and billing workflows. Management’s update on claim processing times and reimbursement yields will be parsed closely for any friction that could defer revenue recognition. Importantly, there is no evidence in current estimates of a material top-line dislocation in the quarter, but the confidence of stakeholders will likely hinge on qualitative color around claim trends and denials, as well as any updates on clarifications and billing modifiers in practical use.

Most promising growth vector to watch

Within the product lineup, the Inspire V platform remains a highlight for growth and a potential lever for future gross margin performance. Investor attention is on the uptake of Inspire V in both new implants and replacement cycles, as the platform’s technical and procedural attributes can influence physician preference, center efficiency, and long-term replacement revenue. The quarter’s commentary on generator availability, lead times, and field inventory will help clarify how quickly customers can transition their standard-of-care mix toward the newer platform. International markets represent an additional opportunity vector for the year, and even though formal segment line-items were not disclosed in the dataset, management’s remarks on center activations, training progress, and geographical expansion will be a key part of the quarter’s narrative. International growth can introduce currency and reimbursement nuances that affect near-term ASPs and margins, but it also expands the installed base and can accelerate multi-year replacement economics once adoption is established. The balance between international momentum and domestic throughput is therefore an important lens for projecting medium-term revenue stability and visibility. Accessory and replacement sales dynamics are another angle that can augment growth and margins. As the installed base expands, replacement cycles and accessory demand typically scale, offering revenue contributions that can be less variable than new system placements. The quarter could provide early reads on replacement mix and cycle timing, which, while minor in a single quarter, set the tone for the year’s recurring revenue profile and operating leverage.

Key stock-price drivers this quarter

The first swing factor for the stock in this print is the revenue and margin trajectory implied by guidance and commentary. With consensus modeling a modest year-over-year revenue increase but negative EBIT and EPS for the quarter, investors will want clarity on whether these headwinds are timing-related or whether they reflect sustained cost and mix pressure. Any color that affirms the revenue growth cadence for 2026—especially relative to the full-year range of 950.00 million to 1.00 billion US dollars discussed earlier this year—will likely influence sentiment around the durability of growth and the shape of recovery in earnings power. The second driver will be gross margin cadence against the fourth-quarter base of 86.59%. While first quarters often bring lower utilization and less favorable mix compared to year-end peaks, management’s guidance on manufacturing efficiencies, component costs, and the impact of Inspire V adoption on cost of goods sold will be read across to the remainder of the year. If the company can demonstrate that gross margin normalization remains on track despite the seasonal trough, it could offset concerns raised by the projected negative EBIT in the quarter and support a more constructive intermediate view on profitability. Operating discipline is the third focal point. Research and development, commercial expansion, and training investments can weigh on near-term operating income, especially when measured against a seasonal revenue trough. Investors will be attuned to whether expense growth is front-loaded in the year or remains proportional to full-year revenue expectations. Commentary that maps operating expenses to revenue growth and gross margin progression would help the market reconcile the first-quarter loss with the company’s pathway to restoring and expanding earnings over subsequent quarters.

Analyst Opinions

Bullish versus bearish ratio in the recent six-month window leans decisively positive: among published ratings explicitly categorized as directional, bullish views outnumber bearish calls by a wide margin, with no outright bearish ratings appearing in our collected set. The tonal balance is bolstered by repeated Buy or Overweight stances from several high-profile firms, which continue to highlight multi-year growth potential, leverage to platform adoption, and a constructive long-term earnings path despite near-term headwinds. Wells Fargo’s Larry Biegelsen maintained a Buy rating with a 160.00 US dollars target, signaling confidence that execution on procedure volumes and center productivity can sustain revenue growth while platform upgrades provide a multi-year margin tailwind. The firm’s vantage point underscores that seasonality and coding-related noise are manageable within the broader trajectory, emphasizing that the installed base growth continues to expand the replacement and accessory opportunity set. Against the current consensus, this framework implies that downside risks embedded in the first-quarter loss forecast may be transitory, provided revenue conversion remains intact and unit economics improve with scale and mix. Morgan Stanley’s Patrick Wood also kept a Buy rating and a 105.00 US dollars target, pointing to the long-run attractiveness of the product platform and the potential for better operating leverage as volume expands. The thesis emphasizes that while quarterly EBIT and EPS can fluctuate with mix and investment timing, the structural profitability profile should benefit from learning-curve effects in manufacturing, expansion of high-margin replacement revenue, and the standardization of newer-platform implants. This view implicitly supports looking through near-term variability if management can articulate a clear cadence for gross margin normalization and expense discipline through the remainder of 2026. Stifel’s Jonathan Block reaffirmed a Buy rating in recent commentary, with targets around 70.00 to 110.00 US dollars in the period, framing current valuation against multi-year revenue and earnings prospects. The notes highlight constructive elements such as sustained demand signals, continued system adoption, and the potential for upside if coding clarifications settle into consistent reimbursement outcomes at provider organizations. From a quarter-to-quarter standpoint, Stifel’s stance aligns with the idea that transitory headwinds in the first quarter may not materially alter the forward revenue trajectory, especially if the company reiterates or refines the full-year revenue range and provides stable throughput and scheduling commentary. Synthesis of the bullish camp centers on three pillars. First, the revenue base is viewed as resilient, with consensus still modeling 3.73% year-over-year growth for the quarter despite seasonality, implying the demand environment has not deteriorated meaningfully. Second, margin recovery remains a focus area, with proponents arguing that the costs and mix dynamics hurting first-quarter EBIT and EPS are either seasonal or transitional rather than structural. Third, platform adoption and installed-base expansion are expected to compound over time, supporting higher-quality, recurring-like revenue streams from replacements and accessories that can improve visibility and operating leverage as adoption deepens. Investors weighing these opinions against the quarter’s setup should center on the specific data points that would validate the bullish narrative. These include: an affirming update on scheduling pipelines and conversion rates; evidence that reimbursement processes are functioning consistently after prior coding clarifications; commentary suggesting a steady roll-out and availability of Inspire V without inventory bottlenecks; and a roadmap for gross margin and operating expense cadence through the next three quarters. If the reported results and qualitative guideposts address these items, the positive skew in analyst sentiment could persist, even as the quarter prints a loss on an EPS basis. Bringing it together, the majority view from influential institutions remains constructive into the report, with Buy-rated analysts emphasizing that first-quarter profitability headwinds are likely a function of seasonal mix and investment timing, not a reset to the long-term earnings algorithm. Their targets embed a recovery in margins as volume scales and product mix tilts toward higher contribution opportunities, a scenario that can be underpinned by sustained procedure growth and consistent reimbursement execution. The degree to which management’s commentary corroborates these assumptions will likely determine whether the post-print reaction tracks the bullish camp’s expectations or prompts a reassessment of near-term earnings power.